| Code | CSB-MP4897MOV |
| Abbreviation | Recombinant Cynomolgus monkey BTLA protein, partial (Active) |
| MSDS | |
| Size | $138 |
| Order now | |
| Image |
|
| Have Questions? | Leave a Message or Start an on-line Chat |
BTLA functions as an inhibitory immune checkpoint receptor that negatively regulates T-cell activation through interaction with herpesvirus entry mediator (HVEM), making it a target of interest in immuno-oncology research. This cynomolgus macaque ortholog, spanning the extracellular domain (residues 31–152) and expressed in mammalian cells to preserve native glycosylation and disulfide bonding, demonstrates quantifiable binding activity with an EC50 of 24.78–31.87 ng/mL against an anti-BTLA recombinant antibody in functional ELISA. The validated binding kinetics support its use in competitive inhibition assays for therapeutic antibody screening, epitope mapping studies to characterize candidate biologics targeting the BTLA–HVEM axis, and SPR or BLI experiments for affinity characterization of checkpoint modulators. With purity exceeding 95% by SDS-PAGE and endotoxin levels below 1.0 EU/μg, this protein meets the quality thresholds commonly required for ligand-binding assays and serves as a positive control in immune checkpoint interaction studies relevant to cancer immunotherapy development.
There are currently no reviews for this product.